

Juergen Kv Reichardt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/697592/publications.pdf>

Version: 2024-02-01

53
papers

1,775
citations

304743

22
h-index

276875

41
g-index

56
all docs

56
docs citations

56
times ranked

2179
citing authors

#	ARTICLE	IF	CITATIONS
1	Human genetics and genomics meetings going virtual: practical lessons learned from two international meetings in early 2020. <i>Human Genomics</i> , 2020, 14, 27.	2.9	8
2	COVID-19 vulnerability: the potential impact of genetic susceptibility and airborne transmission. <i>Human Genomics</i> , 2020, 14, 17.	2.9	95
3	Genomics of COVID-19: molecular mechanisms going from susceptibility to severity of the disease. <i>Human Genomics</i> , 2020, 14, 22.	2.9	4
4	Ecuador's research dream crushed by politics. <i>Nature</i> , 2019, 574, 333-333.	27.8	0
5	The Gut-Brain Axis, Paving the Way to Brain Cancer. <i>Trends in Cancer</i> , 2019, 5, 200-207.	7.4	57
6	Reflections of a Biomedical Scientist on Four Continents in Interdisciplinary Research. <i>Trends in Genetics</i> , 2018, 34, 401-403.	6.7	1
7	Identification of genomic aberrations in hemangioblastoma by droplet digital PCR and SNP microarray highlights novel candidate genes and pathways for pathogenesis. <i>BMC Genomics</i> , 2016, 17, 56.	2.8	21
8	Zinc enhances temozolomide cytotoxicity in glioblastoma multiforme model systems. <i>Oncotarget</i> , 2016, 7, 74860-74871.	1.8	5
9	Effect of Finasteride on Serum Androstenedione and Risk of Prostate Cancer Within the Prostate Cancer Prevention Trial: Differential Effect on High- and Low-grade Disease. <i>Urology</i> , 2015, 85, 616-620.	1.0	8
10	Schwannomas exhibit distinct size-dependent gene-expression patterns. <i>Future Oncology</i> , 2015, 11, 1751-1758.	2.4	3
11	Single Nucleotide Differences (SNDs) Continue to Contaminate the dbSNP Database With Consequences for Human Genomics and Health. <i>Human Mutation</i> , 2015, 36, 196-199.	2.5	8
12	Androgen Receptor CAG Repeat Length and TMPRSS2:ETS Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. <i>Urology</i> , 2014, 84, 127-131.	1.0	6
13	In vitro read-through of phenylalanine hydroxylase (<i>PAH</i>) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria. <i>Journal of Inherited Metabolic Disease</i> , 2013, 36, 955-959.	3.6	20
14	Current progress in using vitamin D and its analogs for cancer prevention and treatment. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 811-837.	2.4	37
15	Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial. <i>Carcinogenesis</i> , 2011, 32, 1500-1506.	2.8	23
16	Transition of a Clinical Trial into Translational Research: The Prostate Cancer Prevention Trial Experience. <i>Cancer Prevention Research</i> , 2010, 3, 1523-1533.	1.5	19
17	Androgen Receptor CAG Repeat Length and Association With Prostate Cancer Risk: Results From the Prostate Cancer Prevention Trial. <i>Journal of Urology</i> , 2010, 184, 2297-2302.	0.4	38
18	Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. <i>Future Oncology</i> , 2010, 6, 1897-1913.	2.4	15

#	ARTICLE	IF	CITATIONS
19	Genomic analysis of cancer tissue reveals that somatic mutations commonly occur in a specific motif. <i>Human Mutation</i> , 2009, 30, 39-48.	2.5	16
20	Androgen-Metabolic Genes in Prostate Cancer Predisposition and Progression. , 2009, , 141-154.		0
21	Realizing the full potential of the sequenced human genome. <i>Trends in Genetics</i> , 2008, 24, 219-220.	6.7	1
22	Pharmacogenomics of brain cancer and personalized medicine in malignant gliomas. <i>Future Oncology</i> , 2008, 4, 525-534.	2.4	27
23	No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned. <i>Human Molecular Genetics</i> , 2008, 17, 2456-2461.	2.9	32
24	Androgens and the molecular epidemiology of prostate cancer. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2008, 15, 261-270.	2.3	23
25	Genomic biomarkers, androgen pathway and prostate cancer. <i>Pharmacogenomics</i> , 2007, 8, 645-661.	1.3	14
26	Unexpected biochemical and pharmacogenetic consequences of SNPs and haplotypes: a cautionary tale for human molecular genetics and epidemiology. <i>Genomics</i> , 2006, 88, 673-674.	2.9	4
27	Genomics in breast and prostate cancer: assessment of the current state and future perspectives. <i>Future Oncology</i> , 2006, 2, 357-362.	2.4	0
28	Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. <i>Molecular Brain Research</i> , 2005, 136, 99-103.	2.3	31
29	Associations between polymorphisms in the steroid 5- α reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer†. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2005, 23, 246-253.	1.6	64
30	Pharmacogenetics of human androgens and prostate cancer – an update. <i>Pharmacogenomics</i> , 2004, 5, 283-294.	1.3	7
31	Molecular Epidemiology of Androgen-Metabolic Loci in Prostate Cancer: Predisposition and Progression. <i>Journal of Urology</i> , 2004, 171, S25-8; discussion S28-9.	0.4	17
32	A renaissance of “biochemical genetics” SNPs, haplotypes, function, and complex diseases. <i>Molecular Genetics and Metabolism</i> , 2004, 83, 47-50.	1.1	14
33	Hormones and prostate cancer: Current perspectives and future directions. <i>Prostate</i> , 2002, 52, 213-235.	2.3	178
34	Association of the G289S single nucleotide polymorphism in the HSD17B3 gene with prostate cancer in Italian men. <i>Prostate</i> , 2002, 53, 65-68.	2.3	51
35	Galactose-1-phosphate uridyl transferase (GALT) genotype and phenotype, galactose consumption, and the risk of borderline and invasive ovarian cancer (United States). <i>Cancer Causes and Control</i> , 2002, 13, 113-120.	1.8	28
36	A Genetic Factor for Age-Related Cataract: Identification and Characterization of a Novel Galactokinase Variant, “Osaka,” in Asians. <i>American Journal of Human Genetics</i> , 2001, 68, 1036-1042.	6.2	80

#	ARTICLE	IF	CITATIONS
37	Multiplex Automated Primer Extension Analysis: Simultaneous Genotyping of Several Polymorphisms. <i>BioTechniques</i> , 2001, 31, 1374-1380.	1.8	85
38	Pharmacogenetics of human androgens and prostatic diseases. <i>Pharmacogenomics</i> , 2001, 2, 65-72.	1.3	18
39	Prostatic Steroid 5 α -Reductase, an Androgen Metabolic Gene. <i>Mayo Clinic Proceedings</i> , 2000, 75, S36-S39.	3.0	1
40	Molecular Basis of Disorders of Human Galactose Metabolism: Past, Present, and Future. <i>Molecular Genetics and Metabolism</i> , 2000, 71, 62-65.	1.1	90
41	A reliable PCR amplification method for microdissected tumor cells obtained from paraffin-embedded tissue. <i>Genetic Analysis, Techniques and Applications</i> , 1999, 15, 229-233.	1.5	16
42	Identification of mutations in the galactose-1-phosphate uridylyltransferase (GALT) gene in 16 Turkish patients with galactosemia, including a novel mutation of F294Y. <i>Human Mutation</i> , 1999, 13, 339-339.	2.5	8
43	Classical galactosemia and mutations at the galactose-1-phosphate uridylyl transferase (GALT) gene. <i>Human Mutation</i> , 1999, 13, 417-430.	2.5	145
44	SOMATIC MUTATIONS AT THE SRD5A2 LOCUS ENCODING PROSTATIC STEROID 5 alpha-REDUCTASE DURING PROSTATE CANCER PROGRESSION. <i>Journal of Urology</i> , 1999, 161, 1355-1358.	0.4	29
45	The fundamental importance of human galactose metabolism: lessons from genetics and biochemistry. <i>Trends in Genetics</i> , 1998, 14, 98-102.	6.7	76
46	Human UDP-Galactose 4 ϵ Epimerase (GALE) Gene and Identification of Five Missense Mutations in Patients with Epimerase-Deficiency Galactosemia. <i>Molecular Genetics and Metabolism</i> , 1998, 63, 26-30.	1.1	47
47	Genetic variation of 3 β -hydroxysteroid dehydrogenase type II in three racial/ethnic groups: Implications for prostate cancer risk. , 1997, 33, 9-12.		63
48	Genetic susceptibility to cancer from exogenous and endogenous exposures. <i>Journal of Cellular Biochemistry</i> , 1996, 63, 15-22.	2.6	46
49	Three new mutations (P183T, V150L, 528insG) and eleven sequence polymorphisms in Italian patients with galactose-1-phosphate uridylyltransferase (GALT) deficiency. , 1996, 8, 369-372.		8
50	Does the racial-ethnic variation in prostate cancer risk have a hormonal basis?. <i>Cancer</i> , 1995, 75, 1778-1782.	4.1	53
51	Correlation of cognitive, neurologic, and ovarian outcome with the Q188R mutation of the galactose-1-phosphate uridylyltransferase gene. <i>Journal of Pediatrics</i> , 1994, 125, 225-227.	1.8	56
52	Characterization of a novel biochemical abnormality in galactosemia: Deficiency of glycolipids containing galactose or N-acetylgalactosamine and accumulation of precursors in brain and lymphocytes. <i>Biochemical Medicine and Metabolic Biology</i> , 1991, 46, 93-104.	0.7	68
53	Molecular analysis of 11 galactosemia patients. <i>Nucleic Acids Research</i> , 1991, 19, 7049-7052.	14.5	10